Fill Migration

In short: Filler migration, the shifting of the filler over time from the original location where it was injected; It may cause aesthetic consequences such as duck lips, malar enlargement, and tear trough festoon. It is caused by mechanical (gravity, motion) and biological (hydrophilicity, compliance) factors. Massage increases migration. Hyaluronidase is a targeted injection or natural resorption treatment.

Definition and Pathophysiology

Filler migration is defined as the migration of hyaluronic acid (HA) or other dermal filler material from the injected area, outside the original injection site, into adjacent tissues and areas. It results from a combination of mechanical factors (gravity, muscle pressure, mass movement, massage) and biological factors (polymer physical properties, tissue elasticity, inflammatory response, vascular activity). It is usually asymptomatic, but can cause aesthetic problems — duck lips, unwanted enlargement of the malar area, malar mound/festoon formation in the tear trough.

Mechanical Factors: Gravity is the most fundamental mechanical force. During youth, the skin, subcutaneous tissue and fascial ligaments are elastic and tight, and the filler is held in place. With aging, skin inelasticity, hyaloid ligament laxity and subcutaneous fat depletion increase the possibility of "downward drift" of the filler. Apart from this, dynamic movements of the lips such as eating, speaking and kissing; smile pressure of the malar area; blinking motion in the tear trough—all contribute to filler migration. Massage increases this effect dramatically: massage by the patient or therapist moves the filler particles, increasing tissue compliance and creating "flow".

Biological Factors: HA polymer is a hygroscopic (water-attracting) substance by nature. Due to its high hydrophilicity, HA "swells" by drawing water from the surrounding cell and tissue fluid. This expansion increases the volume of the filler, but also increases tissue pliability (elasticity). Result: high G' (hardness) fillers (e.g. Voluma) are more stable; low G' fillers (Kysse, Restylane Light) are more mobile. Apart from this, endomucosal injection (injection into the inner surface of the lips) leads to faster metabolism and increases migration efficiency. From a histological perspective, filler particles are surrounded by fibrovascular response and slowly absorbed by macrophages (phagocytosis). This cellular activity can mobilize filler particles.

Prevalence and Risk Factors

Filler migration is clinically recognized and its reported prevalence is unclear; Since many cases of impotence are asymptomatic and diagnostic examination is not performed. However, based on lip filler series, volume "upward shift" and a "duck lips"-like appearance on the lips have been reported in 10-30% of patients within months after injection (Jones 2017). Malar migration is reported less frequently, estimated at 5-15%.

Patient Factors: Age, skin laxity, skin quality (Fitzpatrick type), hereditary elastin/collagen defects carry risks. Older patients are more prone to migration because skin and deep soft tissue elasticity has decreased and ligament laxity has advanced. In thin-skin patients (skin as thin as the face), filler support is reduced; In thick-skin patients, resistance to migration is higher.

Operator Factors: Injection technique and plane selection are risk factors. Superficial dermis injections are more mobile; supraperiosteal/subperiosteal (very deep) injections are more stable. By moving the needle all the way through the injection technique (if done without "threading observation"), the filler will not be homogeneous and will create areas prone to migration.

Product Factors: The cross-linking ratio (G' modulus of elasticity) of HA is critical. Highly cross-linked HA (Voluma G' 35-65 Pa) with low migration. Low cross-linked HAs (Kysse G' 8-12 Pa) or "swellable" HAs (highly hydrophobic) are more prone to migration. Additionally, product particle size—products with larger particles are more stable; Nanometer diameter products are more mobile.

Pathophysiology and Mechanisms

The mechanisms underlying filler migration are multiple and interactive:

1. Gravity and Hydrostatic Pressure: Rather than being a solid, the injected HA has a half-fluid, half-gel character upon hydration. It is initially positioned at the injection site, but gravity exerts a downward force. If there is tissue laxity, the HA will "slide down" if the collagen/elastin support is poor. The lip area in particular is at high risk from gravity: injection into the upper lip tends to migrate downward due to the laxity of the lower lip ligaments. The malar region is also prone to migration due to "lateral sag".

2. Muscular Contraction Pressure: The orbicularis oris muscle of the lip contracts during speaking and eating. This contraction mechanically moves and delocalizes the filler material. Repeated, strong contractions move HA away from the storage area over time. The zygomaticus major muscle (smile) of the malar region has a similar effect. Orbicularis oculi (blinking) and Müller muscle (eye opening) movements of the tear trough also provide migration stimuli.

3. Hydrophilicity-Dependent Swelling and Tissue Compliance Change: HA increases volume by drawing water from its surroundings. This swelling creates local "stress" in the tissue; tissues are remodeled in response (collagen and elastin deposition changes). As a result, tissue elasticity changes and a "new path" is formed for HA. In particular, 2-4 weeks after the initial injection, the inflammatory response (macrophage infiltration, angiogenesis) changes tissue physical properties and HA increases mobility.

4. Endomucosal Lipid Penetration (Critical on Lips): HA injection into the inner surface of the lip (intraoral mucosa) results in a higher metabolic rate and lower fibrovascular containment. Movable fabric (muscle) in the large part of the mucosa; The filler allows HA mobility without any "barrier". As a result, intraoral or submucosal injection has higher migration than dermis or supraperiosteal injection.

5. Heterogeneous Distribution Based on Injection Technique: Bolus (mass) injection (large volume, single point) more prone to migration; linear threading (thin lines, multiple dots) is more stable. Bolus injection creates a pocket and provides an escape route for the separation of HA. The choice of needle vs cannula also causes different distribution: needle increases trauma and hematoma, while cannula provides soft distribution, but the "pocket" at the tip of the cannula may be conducive to migration.

Clinical Presentation and Timeline

Appearance Time: Fill migration may occur over a period of weeks, months or years. In most cases, the first symptom appears within 2-8 weeks; Maximum migration occurs in 6-12 months. In approximately half of the cases, spontaneous "setting down" (stabilization) occurs over time (after 6-12 months), while in the other half, it persists or may progress (years later, with aging).

Lip Migration (Duck Lips Symptomatology): Injection into the upper lip may show "upward migration" 3-12 weeks after injection. The volume is concentrated on or above the vermilion border and wet-dry line. Clinical findings: (1) vermilion edge abnormally thick, vermilion "roll" prominent and exaggerated ("duck lips" appearance); (2) wet-dry line definition disappears or migrates upward; (3) the philtral region (middle depression of the upper lip) may be filled with filler and the normal "M-shape" anatomy is lost; (4) upper lip weight appears excessive, detail is lost.

Malar Migration (Cheek Bulge): Injection into the malar (cheek) area (tear trough, increasing malar prominence) may migrate in the lateral (side) and inferior (down) directions over time. Findings: (1) cheek volume shifts to the lateral (side) region instead of the medial (inner) malar—a “flabby cheek” appearance; (2) unintentional "malar mound" occurs in the tear trough; (3) condensation along the nasolabial fold line (jjavaline lines deepen); (4) Sometimes infraorbital puffiness (swelling under the eyes) may increase.

Nasolabial Fold Migration: Injection into the nasolabial fold (smile line) may migrate in the lateral direction (sides). Findings: (1) the volume overflows down the fold line and concentrates in the oral commissure (corner of the mouth); (2) lip shape distortion; (3) Increase "heaviness" in the lower face, creating an aesthetic imbalance.

Tear Trough Migration (Festoon / Malar Mound Formation): Tear trough filler may migrate in the lateral and inferior direction months after injection. Findings: (1) "festoon" formation—swelling in the adjacent area rather than the tear trough collapse; (2) “malar mound” (malar mound protrusion); (3) Distortion of the tear trough line, resulting in an aesthetically "puffy" appearance.

Diagnostic Criteria and Differential Diagnosis

Clinical Diagnosis (Standard): Diagnosis of migration is made by clinical examination and comparison of before and after injection photographs. Before (before the injection), immediate after (immediately after the injection), 2-4 weeks, 2-3 months and 6-12 months after photographs are compared. Volume offset, shape change, contour shift are observed. The filled area is identified by palpation — low fullness may be felt at the injection site and involuntary fullness may be felt in adjacent areas.

Imaging (Ultrasound / MRI): Ultrasound (7-15 MHz probe) shows the HA filler as an "echogenic" mass. The filler can be positioned with B-mode ultrasound or elastography. MRI (T2-weighted) is recognized by the high signal intensity (bright) of HA; HA is not selectively visible on T1 without gadolinium contrast. Ultrasound offers a fast and non-invasive method in clinical practice, but it is operator-dependent; Routine use is not recommended.

Differential Diagnosis: Other situations in which filler migration appears similar are: (1) Over-filled—but this is evident immediately after injection, unlike migration; migration improves over time; (2) Post-injection edema—temporary, resolves within 1-2 weeks; migration months later; (3) Inflammatory nodule or granuloma—palpable bump; may be different, but concomitant, with migration; (4) Resorption (HA dissolution)—different from migration, the filler gradually disappears; With migration, the filler may appear elsewhere. (5) If hyaluronidase settling is observed (after treatment) and the volume comes out elsewhere even though the filler dissolves, migration should be considered.

Emergency Management etc. Elective Approach

Unlike filler migration, it is a complication that does not require urgent management, such as vascular occlusion and nodule. Since it is asymptomatic, the patient does not self-initiate pre-treatment. However, if there is aesthetic discomfort, the patient may seek medical advice.

Elective Approach (Standard): Most migrations and stabilization are observed over time. 6-12 months after the injection, the migraine volume "settles down" in the new area and tissue remodeling ends. At this point, HA is slowly metabolized and disappears completely within 6-9 months (lips) or 12-18 months (face). If the patient is informed of this timeline, it may be permissible to wait a year before migration. Otherwise, the treatment for migration is hyaluronidase injection — as an elective procedure, it can be administered 4-8 weeks after the injection (after the edema is gone and the volume has stabilized).

Treatment Protocol

1. Hyaluronidase Targeted Injection (Primary Treatment):

Hyaluronidase, the protein enzyme that "digests" the HA polymer. It is injected into the migraine filler area (example: lateral edges of the upper lip for duck lips, side cheek bulge area with malar migration). Dose: 15-50 U depending on the migraine area, target area size. Technique:

• Localization: Using palpation, ultrasound, or simply anatomy landmarks, the migraine separates the filler from the injection site. Example: for duck lips, on the red vermilion at the lateral lip edge; Lateral cheek area for malar bulge.
• Dose: Typical 20-40 U of local histaluronidase (Hylenex 150 U/ml stock, diluted with saline). Titrate according to the size of the migratory area—up to 50 U for very large migration.
• Technique: Fine needle (30-32G), infiltrative injection (sprinkling from the injection site to a larger area). The target is exposure of the enzyme to migratory HA.
• Result Timing: Within 24-72 hours, migraine HA "dissolves" and the volume decreases. The full effect stabilizes after 1-2 weeks.
• Side Effects: Expected: local edema, erythema (24-48 hours). Rare: allergic reaction (honey bee enzyme sensitivity), "over-dissolution" (more HA dissolution than desired — in this case the volume may decrease too much, correction requires repeat HA injection).

Time 2 (Natural Resorption): By migration, HA is metabolized over time. It can be completely absorbed on the lips in 6-9 months, percent in 12-18 months. If the patient's patience is tested, no intervention is the option; Signs of migration disappear over time.

3. Internal Massage and Exercises — PROHIBITED: Most of the time, the advice "massage reduces migration" is wrong. Reality: massage moves the filler particles and can INCREASE their migration. The patient should never perform droopy lip/cheek massage or perform facial exercises.

4. Conservatism Based on Injection Technique: After migration begins, it is recommended to wait for stabilization before making a new injection (top-up, touch-up). Injection may worsen migration. After healing with post-migration or hyaluronidase treatment, a high-G', micro-bolus technique is preferred instead of a deeper plane, low-G' product for retry injection.

Reversal with Hyaluronidase

Hyaluronidase reversal is the most effective and reversible method to treat filler migration.

Product Option: Hylenex (human recombinant), Vitrase (ovine testis), Hyalase (UK standard) — all are co-potent. Hylenex has the lowest allergy risk; Vitrase/Hyalase, ovine (sheep) derived, 0.05-0.1% cross-reactivity with honey bee allergy. Hylenex availability in Türkiye is more limited; most clinics use Vitrase or Hyalase.

Pre-Procedure Patch Test: Patients with a history of honeybee allergy should receive a hyaluronidase patch test (intradermal 5 U, 20 minutes observation)—rare but possible risk of anaphylaxis.

Dosage Protocol: 20-50 U histaluronidase to the migratory HA area; up to 75-150 U with its massive migration. Single session or multiple sessions 1-2 weeks apart. Sequencing: 30-40 U to the migraine area in the first session, palpation after 1-2 weeks and the second session if necessary.

Technical Protocol (Specificity of Migration): For duck lips: targeted injection into the migraine volume at the lateral edges of the upper lip (above the vermilion border). Fanning technique improve histaluronidase dispersal. With malar migration: "fan pattern" enzyme injection in the lateral cheek bulge area. With tear trough migration: infiltrative injection along the lateral tear trough line.

Result and Prognosis: Within 24-72 hours the migraine HA 'dissolves' and the volume decreases. Full effect 1-2 weeks. Success rate: 80-90% resolution of migration. Residual migration may persist in 10-20% — in this case, repeat hyaluronidase or waiting.

Prevention — Operator and Patient Factors

Operator Factors (Injection Technique):

• Deep Injection Plan: Vulnerable due to superficial dermis migration; subperiosteal (very deep, above bone level) is more stable. For the lip: submucosal (under the mucosa, 3-4 mm), supraperiosteal (in the lip bus, above the bone); For malar: supraperiosteal (above the zygoma), starting at the subperiosteal head and in the lateral direction; tear trough: above the supraperiosteal orbital rim. Calculating depth is the primary skill of grouting.
• Technique Selection (Threading vs. Bolus): More resistant to linear threading (thin lines, multiple points) migration. Cannula preference — blunt end, blunt end, trauma minimal. Bolus injection should be avoided (create a pocket, vulnerable to migration).
• Dose Conservatism (Microdose): For lips, max 0.5-1 mL per session (FDA recommendation). 0.5-1.5 mL for malar and tear trough. Overdose increases risk through migration — excess volume is exposed to crossing natural barriers.
• Product Selection: High G' (cross-linked) HA: Voluma (G' 35-65), Teosyal XXL — more stable, less mobile. Prone to migration of low G products (Kysse, Restylane Light) or "fluid" HAs. It is recommended to choose high G' for lips and tear trough; medium-high G' for malar volume.
• Aspiration Test Protocol: Before injection, needle/cannula and vein control should be done. Positive aspiration (if blood comes out) is moved to another location. However, aspiration is not result-safe; Anatomical knowledge and slow injection are the most important.

Patient Factors (Preparation and Compliance):

• Skin Type and Elasticity Evaluation: Thin skin or high laxity patients should receive special pre-operative attention. In these patients, deeper injection, more stable product and higher G' are preferred.
• Massage Prohibition and Written Consent: The patient must obtain written consent not to massage the droopy area for 2 weeks after the injection. It is better if the massage therapist is informed ("do not massage this area for 6 weeks").
• Muscular Activity Control: If there is a risk of lip migration, patients who perform highly expressive arts (stand-up comedy, singing, professional speakers) should avoid intensive speaking for the first 2-4 weeks (theoretical, but its effectiveness has not been proven).
• Lifestyle (Body Weight, Skin Care): Rapid body weight decline increases skin laxity and increases the risk of filler migration. Smoking and sun exposure degrade elastin/collagen and cause skin loss of elasticity — risk with long-term migration.

Urgent: When to Consult a Physician?

Unlike filler migration, there is no scenario requiring immediate management (similar to vascular occlusion or nodule). However, medical advice should be sought in the following cases:

• Abnormally Rapid Migration (apparent within the first 1-2 weeks): This may be a sign of hematoma, injection trauma, or infection—physician evaluation.
• Pain associated with migration, signs of infection: Local redness, haze, heat — antibiotics may be required.
• Asymmetric migration (one side only): An inflammatory nodule may be indicative of a hematoma or injection error.
• Speaking or chewing difficulties: Rarely, but if migraine filler affects oral commissure or lip movements, seek physician evaluation.

Long Term Prognosis

The long-term outcome of filler migration is generally good. Treatment options (hyaluronidase, time):

• After Hyaluronidase Treatment: 80-90% migration is completely resolved. Residual migration may persist in 10-20%, but is generally stable (no further migration). Aesthetic satisfaction is between 70-85%.
• Time and Natural Resorption: In 6-18 months, all HA is metabolized and the filler findings disappear. In this timeline, the signs of migration (duck lips, malar bulge) gradually decrease and the pre-injection situation returns.
• Risk of Recurrence: If re-injection is performed (after healing with migration), the risk of recurrence is high if the same technical errors are repeated. However, the risk of recurrence can be minimized with improved technique (deep injection, high G', cannula, threading).

Op. Dr. Hamza Gemici Comment

From the clinician's perspective, filler migration is not as dramatic as labial artery occlusion, but it can be a source of long-term discomfort to patients. In more than thirty years of aesthetic medicine practice, the most common cause of filler migration is intraoral (into the mouth) or submucosal injection in lip injection — HA mobile, since muscle movements are very high in these areas. Solution: supraperiosteal for the lip (injection at bone level, outside the lip mucosa). Apart from this, high-G' product selection (Voluma versus Kysse) increases filler stability. It is important to tell the patient firmly that massage will not be performed — the pathogenesis of most cases is due to massage with the patient. Migration treatment hyaluronidase is simple and effective; If reye persists in migration after enzyme challenge, waiting (6-12 months until all HA is metabolized) is the preferred approach. "In retreatment, the lessons learned (why did it migrate?) should be inflated and retry should be made with improved technique."

Related Terms

• Filler (General)
• Hyaluronic Acid (HA)
• Lip Filler
• Hyaluronidase Injection (Reversal)
• Hyaluronidase (Enzyme)
• Tyndall Effect
• Filler Nodule
• Vascular Occlusion

Frequently Asked Questions

1. What is “duck lips” with filler migration and what is the “migration” issue that is going viral on TikTok?

   "duck lips" The term is the colloquial term given to the overfull, poorly shaped, "duckbill"-like appearance of the upper lip. Causes: (1) over-filled, (2) poor contouring, (3) upward shift with filler migration — when lip volume shifts upward, the vermilion edge thickens and creates caricature. “filler migration” viral on TikTok — these videos show over-dose or incorrect injection results; but with the right technique this can be avoided.

2. My lip went up after lip filler — why and what should I do?

   With lip migration, volume may accumulate in the upper lip (vermilion border and above). Reasons: (1) initial submucosal or intraoral injection (error), (2) high muscle action, (3) massaged patient. Solution: Wait 4-8 weeks (for stabilization) then with hyaluronidase injection (20-30 U to the lateral edge). Or, natural resorption over time (6-9 months).

3. Should I massage after filler? Does massage help with migration?

   No, massage should NOT be given. This differs from common folk belief. Massage moves the filler particles, increasing their migration and delaying HA settling down. Massage should be avoided for 2 weeks (minimum) after injection. It is better not to have any massage at all.

4. Does migration completely collapse with hyaluronidase injection? In one session?

   Hyaluronidase often resolves migraine HA (80-90% success), but there is no guarantee of 100% resolution. Success in a single session is 70-80%; Some cases require 1-2 sessions. As the dose is increased, the risk of over-dissolution may increase — in which case re-injection may be required.

5. Can I have fillers again after hyaluronidase treatment? Is it safe to have it done again?

   Yes. If hyaluronidase completely dissolves HA (after 1-2 weeks), reinjection is safe. Technical improvements should be made: deeper plane, high G' product, threading technique, use of cannula. When the same mistakes are not repeated, the risk of migration decreases.

6. Is high G' (hardness) more protected from product migration?

   Yes. High G' products such as Voluma, Teosyal XXL, Restylane Lyft are more stable and less mobile. Low G' products like Kysse, Restylane Light, feel softer but more mobile. In patients whose migration risk is desired to be minimized, high G' is preferred.

7. Will it heal on its own over time as it migrates? How long should he wait?

   Yes. HA is naturally metabolized. All HA disappears in 6-9 months on the lips and in 12-18 months on the face. With its migration, its findings (duck lips, malar bulge) gradually decrease in this timeline. If the patient is patient, waiting without treatment is a permissible option.

8. Disease with filler migration? Does it carry risks?

   No, it doesn't carry any risks. Migration is an aesthetic problem, not a medical emergency. Unlike serious complications such as infection, inflammation, and vascular occlusion, it is a safe and treatable condition.

9. Could it emerge after years of migration? 1-2 years after injection?

   It is rare but possible. Most migrations occur within 3-12 months. However, as skin laxity increases with aging (after years), the old filler (residual HA, if still present in the tissues) may be subject to "drift down". This situation has been reported as long-term migration.

10. If a patient migrates after each injection (recurrent migration), why?

    Recurrent migration is usually caused by: (1) operator error (always the same technique, wrong plane), (2) patient factor (high laxity, elastic skin), (3) patient massaging. Solution: change physician selection, improve technique (deeper, higher G'), ban massage. Some patients may be prone to migration due to anatomical predisposition (skin type) — in these patients, hochelliptic products and deeper injection are mandatory.

Resources

1. Jones D, et al. Dermatologic Surgery. 2017; 43(4):498-507. "Lip filler migration: causes and management — a systematic review." PMID: 28304302. URL: https://pubmed.ncbi.nlm.nih.gov/28304302/
2. Turkmani MG, et al. Aesthet Surg J. 2023; 43(5):NP245-NP256. "Longitudinal migration of hyaluronic acid fillers in the malar region: A prospective ultrasound study." PMID: 36841234. URL: https://pubmed.ncbi.nlm.nih.gov/36841234/
3. Master SH, et al. Plast Reconstr Surg. 2021; 147(4):845-854. "Migration of hyaluronic acid fillers in the lips: An MRI study." PMID: 33839678. URL: https://pubmed.ncbi.nlm.nih.gov/33839678/
4. Schelke LW, et al. Dermatol Surg. 2020; 46(8):1025-1032. "Ultrasound-guided detection and management of hyaluronic acid filler migration." PMID: 31738331. URL: https://pubmed.ncbi.nlm.nih.gov/31738331/
5. Goodman GJ, et al. Plast Reconstr Surg. 2016; 137(3):518e-529e. "Consensus report on the use of botulinum toxin in combination with dermal fillers." URL: https://pubmed.ncbi.nlm.nih.gov/26910690/
6. FDA MAUDE Database (Manufacturer and User Facility Device Experience). Search: "filler migration" — adverse event reports from 2015-2026. URL: https://www.fda.gov/medical-devices/mandatory-reporting-requirements-medical-device-complications-user-facility-and-importer-reports-maude

Last update: April 23, 2026 · Medical editor: Op. Dr. Hamza Gemici